The FDA has granted a final approval to pemetrexed for injection (Pemfexy), an alternative to standard pemetrexed (Alimta) for the treatment of patients with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) and for those with malignant pleural mesothelioma.
“This agreement provides for a release of all claims by the parties and allows for an initial entry of Pemfexy into the market, equivalent to approximately a three-week supply of current Alimta utilization, on February 1, 2022, and a subsequent uncapped entry on April 1, 2022,” Eagle Pharmaceuticals stated in the press release.
Eagle Pharmaceuticals receives final FDA approval for Pemfexy (pemetrexed for injection) [news release]: Woodcliff Lake, NJ. Eagle Pharmaceuticals. Published February 10, 2020. https://bit.ly/2SircfX. Accessed February 10, 2020.
... to read the full story